Analysis Of Efficacy Of Intraperitoneal Hypetrhermic Perfusion Combined With Intravenous Chemotherapy On Postoperative Epithelial Ovarian Cancer

Objective:To investigate the curative effect and the side effects of intraperitoneal hyperthermalchemotherapy (IPHC) on ovarian carcinoma after cytoreductive surgery. This studyprovides further promotion and clinical evidence for the peritoneal perfusion chemotherapy,which seeks more reasonable comprehensive treatment programs for the ovarian cancer.Methods:Retrospective analysis of the clinical data of97patients with diagnosed ovariancancer in our hospital from January2007to April2012was conducted. In the treatmentgroup,45patients were treated by intraperitoneal hyperthermal chemotherapy combinedwith intravenous chemotherapy; in the control group,52patients were treated byintravenous chemotherapy. The progress of the disease and the curative effect and the sideeffects were analysed.Results:1. PFS1: For the first-line treatment of patients, the progression-free survival was42.0months in the treatment group and21.0months in the control group. The difference wasstatistically significant(P<0.05).2. PFS2: For the platinum-sensitive relapse patients, the progression-free survival was15.0months in the treatment group and12.0months in the control group. The differencewas not statistically significant(P>0.05). For the platinum-resistant recurrence patients, theprogression-free survival was18.0months in the treatment group and3.0months in thecontrol group. The difference was statistically significant（P<0.05）.3. Survival rates in3-year and5-year: The survival rates in3-year and5-year were 90.3%%and70.3%in the treatment group, respectively, whereas in the control group, therates were64.6%and43.0%, respectively. The difference of the survival curves wasstatistically significant（P<0.05）.4. Prognostic univariate analysis: the pathological stage, the residual tumor diameter,the first-line chemotherapy cycles and the CA125levels after three cycles of chemotherapywere prognostic factors of ovarian cancer.5. Multivariate analysis of prognostic factors: the pathological grade, the residualtumor diameter, the front-line chemotherapycycles and the CA125levels after three cyclesof chemotherapy were independent prognostic factors.6. The common adverse reactions were the bone marrow suppression，the liver andkidney function damage，the gastrointestinal reaction，the hair loss and the peripheral nervetoxicity and so on. The incidence of adverse reaction between the two groups had nosignificant differences(P>0.05).Conclusions:1. For the adjuvant therapy of theⅡ~Ⅳ epithelial ovarian cancer, the intraperitonealhyperthermal chemotherapy combined with intravenous chemotherapy is superior to theintravenous chemotherapy.2. For the recurrent epithelial ovarian cancer patients, the intraperitoneal hyperthermalchemotherapy combined with intravenous chemotherapy is superior to the intravenouschemotherapy.3. The Poorly differentiated pathology, the residual tumor diameter≥1cm, thefirst-line chemotherapy cycles <6, the CA125level within three cycles of chemotherapy>35u/ml were poor prognostic factors of epithelial ovarian cancer.5. The intraperitoneal hyperthermal chemotherapy combined with intravenouschemotherapy did not increase the adverse reactions significantly.